Paper II — 2024 December (Supplementary) (2019 Scheme) — Qxiv
3 min read
Paper II
2024 December (Supplementary) (2019 Scheme) · 100 marks · 180 min
Question
(A) Intravesical administration of BCG (Bacillus Calmette Geurin) is a treatment for bladder carcinoma
(R) BCG elicits granulomatous inflammation and local anti tumour immune response.
a) Both A & R are correct and R is the reason for A
b) Both A & R are correct but R is not reason for A
c) A is correct R is incorrect
d) A is incorrect R is correct
Qxiv1 marksMCQs
Answer
Correct answer: a) Both A & R are correct and R is the reason for A
Both statements are correct, and R explains A. Intravesical BCG instillation is standard treatment for high-risk non-muscle-invasive (superficial) bladder carcinoma. It works by inducing a local granulomatous inflammatory reaction in the bladder wall, which recruits and activates immune effector cells (macrophages, cytotoxic T cells, NK cells) that mount an anti-tumour immune response — directly explaining its therapeutic effect described in A.